Pharma Companies Struggle to Meet Diversity Goals in Clinical Trials
Despite the rhetoric around diversity and inclusion in clinical trials, many pharma companies are still falling short when it comes to achieving diversity targets. A recent survey revealed that only 24% of clinical trial professionals are actively benchmarking disease demographics against enrolled populations, indicating a significant gap in diversity efforts.
Katrina Rice, the chief delivery officer at eClinical Solutions, pointed out that while companies have been vocal about the importance of trial diversity, there is often a lack of data to support their claims. This has left room for improvement and growth in the industry’s approach to diversity and inclusion.
However, a new challenge is emerging on the horizon. Healthcare costs are projected to rise in 2026, with Americans facing increased premiums and employers grappling with higher benefit costs. These financial burdens could potentially deter individuals from participating in clinical research studies, as the indirect costs associated with participation, such as travel and lodging, remain a significant barrier.
Despite efforts by pharma companies to offer compensation for trial participation, a survey of clinical study participants across various therapeutic areas revealed that 58% did not receive payment for trial-related costs. This lack of financial support, coupled with rising healthcare expenses, could further hinder diversity in clinical trials, particularly among lower-income populations.
To address these challenges and stay on track with diversity goals, the industry must prioritize communication, access, and trust-building. Pharma companies need to effectively communicate the benefits of participating in clinical trials and work towards broadening access to research sites. Leveraging technology, such as AI, can help pinpoint the right areas for clinical sites and facilitate study design for more diverse populations.
Additionally, building trust with communities and ensuring diversity within the industry itself are crucial factors in promoting inclusivity in clinical trials. By actively engaging with diverse communities, attending health fairs, and being visible in the areas they serve, pharma companies can demonstrate their commitment to diversity and inclusion.
Ultimately, progress in achieving diversity goals in clinical trials will be measured not just by numbers, but by the industry’s active presence and engagement with the communities they aim to serve. By integrating diversity into all aspects of their operations, from research to recruitment, pharma companies can work towards creating more inclusive and representative clinical trials.
